Introducing Real Chemistry’s SiteView Platform: Integrating Oncology Data in One Place

One could be forgiven for thinking that the volume of data and AI – both in conversation and substance – has been cranked up to 11. The healthcare industry is witnessing an explosion of data sources – open and closed claims, lab, EHR, consumer, affiliations – and an ever-increasing level of accessibility. Like any advancement in technology, this comes with expected tradeoffs. Data breadth and velocity are a boon to organizations with mature analytics capabilities that can mine datasets – informing strategy and tactical operations alike. At the same time, integrating disparate datasets and gleaning insights can be cost-prohibitive and highly challenging. This is especially pronounced for the 30% of oncology companies who are seeking to bring their first treatment to market.

We know – both intuitively and through formal FDA guidance – that the role of real-world data (RWD) will only increase over time. One role can take the form of identifying appropriate patient populations through empirical clinical data, including diagnoses, past treatment experience or biomarker availability. RWD is also being applied to identify patients from historically underrepresented racial and ethnic groups. The FDA has issued draft guidance that biopharma companies should formulate a robust diversity action plan, taking into account the race and ethnic composition of patients at a disease epidemiology level, and recruit patients for clinical trials with an eye toward equity and inclusion. Companies that can proactively foster inclusivity in their trials stand to not only correct historical inequities, but also avoid potential inquiries from the FDA and other regulatory bodies.

Real Chemistry can support oncology-focused companies in identifying appropriate patients, selecting viable sites and integrating data in a meaningful way. The team at our data and AI engine, IPM.ai, constructed a clever solution that can drive impact for biopharma companies of any size. This proprietary platform – SiteView – uniquely bridges leading data assets across the marketplace to deliver detailed analytics to oncology companies.

For every hospital in the U.S., SiteView will contain most of the relevant datapoints (see table below for examples) to inform site selection and participant recruitment. Specifically, SiteView provides:

1. Site-Level Visibility – Spanning a single, consolidated report, SiteView contains all hospitals and systems with past or active oncology clinical trials. Each institution will contain detailed metrics that are rolled up to the organization.

2. Integrated Metrics – The power of SiteView comes from the absolute values of patients, providers or trials that sit within each institution. Specific to solid tumors or hematologic cancers, SiteView will contain:

• Total number of patients (diagnosed and treated)

• Patients who have participated in clinical trials

• Number of treating oncologists

• Diversity breakdown (see chart below)

• Number of past trials

• Number of active trials

3. Geographic and Tabular Visualization – Each SiteView report contains heatmaps by patient volume and granular reports containing a 360⁰ view of each institution.

Oncology companies equipped with best-in-class RWD, social determinants of health, affiliations and clinical analytics can make more informed decisions about where they place their efforts and investments. SiteView is available “out-of-the-box” for rapid intelligence at economy pricing or can be further customized to deliver insights at the HCP level using nuanced business rules.

Our team is eager to share more and walk you through SiteView at ASCO.

To learn more about how SiteView can deliver detailed analytics, please reach out to dfisher@realchemistry.com or ikouchlev@realchemistry.com. If you will be at ASCO 2023 in Chicago, we can set up a meeting.